FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053233072> ?p ?o ?g. }

• W2053233072 abstract "Hormonal therapy (HT) is an important consideration in the management of postmenopausal women with metastatic breast cancer. Despite the fact that the advanced-stage disease is virtually incurable, HTs can offer patients disease control equivalent to that of chemotherapy, but with improved quality of life (QOL). Knowledge of the estrogen and progesterone receptor status, as well as other clinical factors, allows for selection of patients who are most likely to benefit from HT. Disease that becomes refractory to an initial HT may respond to another agent or class of HTs. Thus, HTs are generally administered sequentially, delaying the need for cytotoxic chemotherapy, which often reduces QOL. Optimal sequencing is thus one of the more important facets of HT. Prior to the release of a number of newer agents, tamoxifen had been considered as initial HT. At present, more agents exist, including the aromatase inhibitors, progestins, and the estrogen receptor antagonist fulvestrant.This article reviews key trials evaluating the use of sequential HTs.Articles were identified for inclusion in this manuscript through the following searches, limited to English-language publications: MEDLINE (mid 1960s to January 2002), American Society of Oncology abstracts (1997-2001), and San Antonio Breast Cancer Symposium abstracts (2001 and 2002). The following search terms were used: breast cancer, hormonal therapies, tamoxifen, toremifene, letrozole, anastrozole, exemestane, megestrol acetate, fulvestrant, and ICI 182,780.Results of Phase III studies have shown many of these agents to be equivalent or superior to tamoxifen and can be used initially to treat patients who either have failed tamoxifen therapy or may be unable to tolerate some of the toxicities associated with tamoxifen. For example, the aromatase inhibitors have been shown to be highly active and tolerable in postmenopausal women with breast cancer who have failed tamoxifen therapy or who are naive to HT. Other clinical trials have demonstrated the efficacy of fulvestrant in patients with metastatic breast cancer who are tamoxifen-resistant, and have shown fulvestrant to be at least as effective as anastrozole in tamoxifen-resistant patients.Although the optimum sequence of HTs remains controversial, using the newer agents as initial or subsequent therapy should improve QOL and may improve overall survival." @default.
• W2053233072 created "2016-06-24" @default.
• W2053233072 creator A5016380475 @default.
• W2053233072 date "2002-01-01" @default.
• W2053233072 modified "2023-09-26" @default.
• W2053233072 title "Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer" @default.
• W2053233072 cites W1562190372 @default.
• W2053233072 cites W1573126284 @default.
• W2053233072 cites W1918073772 @default.
• W2053233072 cites W1934173384 @default.
• W2053233072 cites W1943320567 @default.
• W2053233072 cites W196157878 @default.
• W2053233072 cites W1968450987 @default.
• W2053233072 cites W1990603654 @default.
• W2053233072 cites W1991975509 @default.
• W2053233072 cites W1993837674 @default.
• W2053233072 cites W1996824135 @default.
• W2053233072 cites W2018667612 @default.
• W2053233072 cites W2025233460 @default.
• W2053233072 cites W2031911117 @default.
• W2053233072 cites W2042162210 @default.
• W2053233072 cites W2054664904 @default.
• W2053233072 cites W2057879841 @default.
• W2053233072 cites W2057998221 @default.
• W2053233072 cites W2063261073 @default.
• W2053233072 cites W2070386287 @default.
• W2053233072 cites W2073310837 @default.
• W2053233072 cites W2076095672 @default.
• W2053233072 cites W2077114772 @default.
• W2053233072 cites W2082382339 @default.
• W2053233072 cites W2088006738 @default.
• W2053233072 cites W2109509181 @default.
• W2053233072 cites W2120816980 @default.
• W2053233072 cites W2141647078 @default.
• W2053233072 cites W2172185687 @default.
• W2053233072 cites W2180492527 @default.
• W2053233072 cites W2202169216 @default.
• W2053233072 cites W2398634514 @default.
• W2053233072 cites W2399969386 @default.
• W2053233072 cites W2416273130 @default.
• W2053233072 cites W2461551798 @default.
• W2053233072 cites W2508460892 @default.
• W2053233072 cites W2588806883 @default.
• W2053233072 cites W518170 @default.
• W2053233072 cites W1983555349 @default.
• W2053233072 cites W2520375087 @default.
• W2053233072 doi "https://doi.org/10.1016/s0149-2918(02)85160-8" @default.
• W2053233072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12117075" @default.
• W2053233072 hasPublicationYear "2002" @default.
• W2053233072 type Work @default.
• W2053233072 sameAs 2053233072 @default.
• W2053233072 citedByCount "3" @default.
• W2053233072 countsByYear W20532330722018 @default.
• W2053233072 crossrefType "journal-article" @default.
• W2053233072 hasAuthorship W2053233072A5016380475 @default.
• W2053233072 hasConcept C121608353 @default.
• W2053233072 hasConcept C126322002 @default.
• W2053233072 hasConcept C143998085 @default.
• W2053233072 hasConcept C2775860665 @default.
• W2053233072 hasConcept C2775930923 @default.
• W2053233072 hasConcept C2776067312 @default.
• W2053233072 hasConcept C2776215463 @default.
• W2053233072 hasConcept C2777176818 @default.
• W2053233072 hasConcept C2778311097 @default.
• W2053233072 hasConcept C2778812593 @default.
• W2053233072 hasConcept C2780482068 @default.
• W2053233072 hasConcept C29456083 @default.
• W2053233072 hasConcept C530470458 @default.
• W2053233072 hasConcept C71924100 @default.
• W2053233072 hasConceptScore W2053233072C121608353 @default.
• W2053233072 hasConceptScore W2053233072C126322002 @default.
• W2053233072 hasConceptScore W2053233072C143998085 @default.
• W2053233072 hasConceptScore W2053233072C2775860665 @default.
• W2053233072 hasConceptScore W2053233072C2775930923 @default.
• W2053233072 hasConceptScore W2053233072C2776067312 @default.
• W2053233072 hasConceptScore W2053233072C2776215463 @default.
• W2053233072 hasConceptScore W2053233072C2777176818 @default.
• W2053233072 hasConceptScore W2053233072C2778311097 @default.
• W2053233072 hasConceptScore W2053233072C2778812593 @default.
• W2053233072 hasConceptScore W2053233072C2780482068 @default.
• W2053233072 hasConceptScore W2053233072C29456083 @default.
• W2053233072 hasConceptScore W2053233072C530470458 @default.
• W2053233072 hasConceptScore W2053233072C71924100 @default.
• W2053233072 hasLocation W20532330721 @default.
• W2053233072 hasLocation W20532330722 @default.
• W2053233072 hasOpenAccess W2053233072 @default.
• W2053233072 hasPrimaryLocation W20532330721 @default.
• W2053233072 hasRelatedWork W1981372598 @default.
• W2053233072 hasRelatedWork W1983497273 @default.
• W2053233072 hasRelatedWork W1992542780 @default.
• W2053233072 hasRelatedWork W1993069537 @default.
• W2053233072 hasRelatedWork W2014342211 @default.
• W2053233072 hasRelatedWork W2018742272 @default.
• W2053233072 hasRelatedWork W2035185437 @default.
• W2053233072 hasRelatedWork W2038645467 @default.
• W2053233072 hasRelatedWork W2046713166 @default.
• W2053233072 hasRelatedWork W2060387063 @default.
• W2053233072 hasRelatedWork W2084169190 @default.
• W2053233072 hasRelatedWork W2091556761 @default.
• W2053233072 hasRelatedWork W2117301449 @default.

• next